OverviewSuggest Edit
Zynex is a company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include an electrical nerve stimulation device, and electromyography triggered an electrical stimulation device, as well as a device for the treatment of female urinary incontinence.
| Type | Public | |
| Founded | 1996 | |
| HQ | Englewood, CO, US | Map |
| Website | zynex.com | |
| Employee Ratings | More |
Key People/Management at Zynex
Thomas Sandgaard
Chairman of the Board, President, and Chief Executive Officer
Dan Moorhead
Chief Financial Officer
Joseph Papandrea
Chief Operating Officer
Chelle van Burkleo
VP of Sales
Raelynn Maloney
Director of Communications and Organizational Development
Anna Lucsok
VP of Reimbursement
Zynex Office Locations
Zynex has offices in Englewood and Lone Tree
Englewood, CO, US (HQ)
9555 Maroon Cir
Lone Tree, CO, US
9990 Park Meadows Dr
Zynex Financials and Metrics
Zynex Revenue
Zynex's revenue was reported to be $45.47 m in FY, 2019
| USD | |
|---|---|
Revenue (Q3, 2020) | 20.0m |
Gross profit (Q3, 2020) | 15.7m |
Gross profit margin (Q3, 2020), % | 78.5% |
Net income (Q3, 2020) | 1.3m |
EBIT (Q3, 2020) | 1.4m |
Market capitalization (15-Jan-2021) | 574.7m |
Closing stock price (15-Jan-2021) | 16.5 |
Cash (30-Sept-2020) | 41.2m |
EV | 538.6m |
Zynex's current market capitalization is $574.7 m.
Annual
Quarterly
| USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 8.4m | 9.4m | 8.9m | 10.0m | 10.1m | 7.7m | 5.5m | 5.2m | 3.2m | 1.3m | 4.4m | 3.2m | 3.1m | 2.7m | 3.5m | 3.3m | 3.6m | 3.4m | 5.0m | 6.8m | 6.9m | 7.6m | 8.1m | 9.2m | 10.3m | 11.8m | 15.2m | 19.3m | 20.0m |
Cost of goods sold | 1.7m | 1.9m | 1.8m | 1.8m | 2.2m | 2.2m | 1.9m | 1.5m | 997.0k | 903.0k | 1.2m | 1.1m | 1.1m | 726.0k | 983.0k | 941.0k | 880.0k | 923.0k | 1.0m | 1.3m | 1.2m | 1.3m | 1.6m | 1.8m | 1.9m | 2.3m | 3.4m | 4.1m | 4.3m |
Gross profit | 6.7m | 7.5m | 7.1m | 8.2m | 7.9m | 5.5m | 3.6m | 3.6m | 2.2m | 446.0k | 3.2m | 2.1m | 2.0m | 1.9m | 2.5m | 2.3m | 2.7m | 2.5m | 4.0m | 5.5m | 5.6m | 6.2m | 6.5m | 7.4m | 8.3m | 9.6m | 11.8m | 15.2m | 15.7m |
Gross profit Margin, % | 79% | 79% | 80% | 82% | 78% | 71% | 66% | 70% | 69% | 33% | 73% | 65% | 65% | 73% | 72% | 71% | 76% | 73% | 80% | 80% | 82% | 82% | 80% | 81% | 81% | 81% | 78% | 79% | 79% |
Annual
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 789.0k | 823.0k | 323.0k | 63.0k | 8.0k | 247.0k | 5.6m | 10.1m | 14.0m |
Accounts Receivable | 11.0m | 12.2m | 7.0m | 3.2m | 2.4m | 3.0m | 2.2m | 2.8m | 5.8m |
Prepaid Expenses | 293.0k | 243.0k | 346.0k | 250.0k | 27.0k | 40.0k | 198.0k | 570.0k | 315.0k |
Inventories | 4.6m | 6.2m | 5.0m | 1.9m | 305.0k | 107.0k | 423.0k | 837.0k | 2.4m |
Quarterly
| USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 783.0k | 761.0k | 742.0k | 623.0k | 843.0k | 681.0k | 445.0k | 468.0k | 189.0k | 311.0k | 319.0k | 348.0k | 87.0k | 41.0k | 24.0k | 29.0k | 91.0k | 462.0k | 140.0k | 2.6m | 4.4m | 6.3m | 8.1m | 9.4m | 10.1m | 11.9m | 14.6m | 16.9m | 41.2m |
Accounts Receivable | 9.5m | 10.8m | 11.6m | 12.1m | 12.3m | 11.2m | 9.8m | 8.8m | 6.3m | 5.0m | 4.5m | 2.9m | 2.7m | 2.8m | 3.2m | 3.2m | 4.0m | 2.9m | 2.5m | 2.4m | 2.7m | 2.9m | 2.9m | 3.1m | 3.5m | 4.3m | 6.5m | 7.3m | 9.4m |
Prepaid Expenses | 136.0k | 146.0k | 304.0k | 202.0k | 210.0k | 256.0k | 194.0k | 178.0k | 244.0k | 173.0k | 37.0k | 191.0k | 130.0k | 40.0k | 20.0k | 123.0k | 28.0k | 148.0k | 125.0k | 211.0k | 615.0k | 579.0k | 364.0k | 738.0k | 833.0k | 321.0k | 1.1m | 804.0k | 1.1m |
Inventories | 3.8m | 4.3m | 5.6m | 6.6m | 6.7m | 6.3m | 5.8m | 6.1m | 5.0m | 2.6m | 2.5m | 1.6m | 1.4m | 1.1m | 173.0k | 164.0k | 96.0k | 128.0k | 178.0k | 358.0k | 710.0k | 518.0k | 796.0k | 968.0k | 1.3m | 2.1m | 3.4m | 4.7m | 5.9m |
Annual
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.6m | 1.6m | (7.3m) | (6.2m) | (2.9m) | 69.0k | 7.4m | 9.6m | 9.5m |
Depreciation and Amortization | 806.0k | 864.0k | 839.0k | 660.0k | 424.0k | 435.0k | 286.0k | 448.0k | 778.0k |
Inventories | (1.0m) | (2.1m) | (279.0k) | 726.0k | 1.6m | 198.0k | (316.0k) | (414.0k) | (2.4m) |
Accounts Payable | 876.0k | (132.0k) | 686.0k | (199.0k) | (67.0k) | 402.0k | (1.2m) | (515.0k) | 785.0k |
Quarterly
| USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 374.0k | 965.0k | 320.0k | 793.0k | 1.2m | (304.0k) | (2.0m) | (2.8m) | (1.4m) | (7.0m) | (6.7m) | 2.9m | 6.0m | 7.3m | |||||||||||||||
Depreciation and Amortization | 389.0k | 594.0k | 213.0k | 432.0k | 647.0k | 213.0k | 417.0k | 647.0k | 156.0k | 309.0k | 469.0k | 252.0k | 537.0k | 1.0m | |||||||||||||||
Inventories | (93.0k) | (791.0k) | (995.0k) | (2.1m) | (2.3m) | (181.0k) | 123.0k | (265.0k) | (23.0k) | 400.0k | 186.0k | (1.5m) | (2.4m) | (4.3m) | |||||||||||||||
Accounts Payable | 145.0k | 848.0k | 335.0k | 516.0k | 264.0k | (382.0k) | 51.0k | 232.0k | 162.0k | 258.0k | 2.0k | 162.0k | 189.0k | 1.6m |
| USD | Q2, 2011 |
|---|---|
Financial Leverage | 2.1 x |
Zynex Cybersecurity Score
Zynex Environment, Social & Governance (ESG) Ratings
Zynex Online and Social Media Presence
Zynex's Trends
Zynex News and Updates
October 23, 2020
Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division
ENGLEWOOD, Colo., Oct. 23, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...
July 15, 2020
Zynex, Inc. Prices Public Offering of Common Stock
ENGLEWOOD, Colo., July 14, 2020 /PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological...
December 02, 2019
Zynex to Present at the Piper Jaffray 31st Annual Healthcare Conference
ENGLEWOOD, Colo., Dec. 2, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...
October 02, 2019
Zynex Announces 95% Order Growth
ENGLEWOOD, Colo., Oct. 2, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today...
June 12, 2019
Zynex to Present at Raymond James Life Sciences and MedTech Conference
ENGLEWOOD, Colo., June 12, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...
February 07, 2019
Zynex Announces Uplisting to The Nasdaq Capital Market
ENGLEWOOD, Colo., Feb. 7, 2019 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, is...
Zynex Blogs
January 14, 2021
Zynex Announces Filing of Patent for Sepsis Monitor
November 19, 2020
Zynex Ranked 13th in Revenue Growth Among Medical Device Companies
October 27, 2020
Zynex Announces Third Quarter 2020 Earnings
Zynex Frequently Asked Questions
When was Zynex founded?
Zynex was founded in 1996.
Who are Zynex key executives?
Zynex's key executives are Thomas Sandgaard, Dan Moorhead and Joseph Papandrea.
How many employees does Zynex have?
Zynex has 283 employees.
What is Zynex revenue?
Latest Zynex annual revenue is $45.5 m.
What is Zynex revenue per employee?
Latest Zynex revenue per employee is $160.7 k.
Who are Zynex competitors?
Competitors of Zynex include Theraclion, Shockwave Medical and Kallo.
Where is Zynex headquarters?
Zynex headquarters is located at 9555 Maroon Cir, Englewood.
Where are Zynex offices?
Zynex has offices in Englewood and Lone Tree.
How many offices does Zynex have?
Zynex has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies